Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stanford University
This study is an open-label pilot study. Participants will be treated with oral tofacitinib for 3 months.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age \>= 18 years old
Diagnosis of alopecia areata with \>50% scalp involvement, alopecia totalis, or alopecia universalis
Hair loss present for at least 6 months
No treatment for alopecia areata in past 2 months
No evidence of hair regrowth
Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication
Fluent in spoken and written English
You may not be if
Age \<18 years old
Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study
Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
Patients known to be HIV or hepatitis B or C positive
Patients with positive tuberculin skin test or positive QuantiFERON TB test
Patients with leukopenia or anemia
Patients with renal or hepatic impairment
Patients with peptic ulcer disease
Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors
Women of childbearing potential who are unable or unwilling to use birth control while taking the medication
Women who are pregnant or nursing
Clareo Health | Tofacitinib for the Treatment of Alopecia Areata and Its Variants
